Tom Needham Email & Phone Number

Specialties: Life Sciences, Venture Capital, Biotechnology/Pharmaceuticals, Medical TechnologyTom Needham is a Director and Head of the Biopharmaceuticals practice at Broadview Ventures.Tom has 30 years of experience in venture capital, business development, corporate strategy, and C-suite executive management responsibilities in public and private life science companies. Tom currently serves on the boards of Basking Biosciences, including serving as Chairman (2020 thru 2023) and IsomAb, as well as holds board observer roles at Comanche Bio and HAYA Therapeutics. Previously, Tom represented Broadview on the board at Antag Therapeutics, Renovacor (NYSE: RCOR, acquired by Rocket Pharma), including serving as Renovacor’s Chairman (2019 thru 2021), and held board observer roles at NIDO Surgical (acquired), and Cardero Therapeutics (now Epirium Bio). Tom’s prior venture investment experience also includes working on Astex Pharmaceuticals (NASDAQ: ASTX, acquired by Otsuka), Enanta Pharmaceuticals (NASDAQ: ENTA), MD Everywhere (acquired by Marlin Equity Partners), Sirion Therapeutics (trade sale to Alcon and Bausch & Lomb) and Aegerion Pharmaceuticals (NASDAQ: AEGR).Prior to joining Broadview Ventures, Tom was most recently Chief Business Officer at Merrimack Pharmaceuticals (Nasdaq: MACK) and Senior Vice President, Business Development at C4 Therapeutics (NASDAQ: CCCC). Prior to C4T, Tom spent 13 years as a venture capital investor, most recently as a Managing Director at Synthesis Capital, where he was involved in the management of two healthcare venture funds focused on investments in biotechnology, pharmaceuticals and medical technology. Prior to Synthesis, Tom was a Principal at Advent International, a global private equity firm, as a member of the healthcare venture capital deal team in Boston. Earlier in his career, Tom held Vice President of Business Development positions at private and public biotech companies, where he led the negotiation and closing of a number of strategic transactions, including R&D partnerships with global pharmaceutical companies, licensing and M&A transactions. Tom holds a B.A. from Bowdoin College and an MBA from Babson College’s F.W. Olin Graduate School of Business.

Listed skills include Venture Capital, Biotechnology, Business Development, Pharmaceutical Industry, and 30 others.